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Abstract
Background: Caveolin-1 is the main component of caveolae membrane structures and has different roles during
tumorigenesis in different cancer types with varying expression profiles, indicating that the role of caveolin-1 varies
according to tumor type. In this study, we investigated the role and expression of caveolin-1 in hepatocellular
carcinogenesis.
Methods: We analyzed the expression of Caveolin-1 in 96 hepatocellular carcinoma (HCC), 29 cirrhosis, 20 normal
liver tissues and 9 HCC cell lines by immunostaining and western blotting, respectively. After caveolin-1 was stably
transfected to HepG2 and Huh7 cells, the effects of Caveolin-1 on the cellular motility, matrix invasion and anchorage-
independent growth were studied. Also, caveolae structure was disrupted in endogenously caveolin expressing cells,
SNU 449 and SNU 475 by addition of methyl-β-cyclodextrin and analyzed cellular motility and invasion.
Results: In HCC cell lines, Caveolin-1 expression is correlated to differentiation and basal motility status of these cells.
The percentage of Caveolin-1 positivity was found extremely low in normal liver tissue (5%) while it was increased in
cirrhosis (45%) and in HCC (66%) (p = 0.002 and p = 0.001 respectively). Cav-1 expression in poorly differentiated HCC
samples has been found significantly higher than well differentiated ones (p = 0.001). The caveolin-1 expression was found
significantly higher in tumor cells than its peritumoral cirrhotic tissues in HCC samples (p < 0.001). Additionally, the
patients with positive staining for Caveolin-1 had significantly higher portal vein invasion than those with negative staining
(p = 0.02). Caveolin-1 overexpression increased motility and invasion of HepG2 and Huh7 cells. And disruption of
caveolae results in a dramatic decline in both motility and invasion abilities in SNU-449 and SNU-475 cells. Furthermore,
caveolin-1 overexpression resulted in down-regulation of E-cadherin while up-regulation of Vimentin. Also, it increased
secreted MMP-2 and expression levels of MMP-9 and MT1-MMP. There was no significant difference in colony formation
in soft agar between stable clones and parental ones.
Conclusion: In conclusion, stepwise increase in Cav-1 expression in neoplastic stage with respect to pre-neoplastic
stage during hepatocellular carcinogenesis and its ability to stimulate HCC cell motility and invasiveness indicate that this
protein plays a crucial role in tumor progression.
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Background
Dysregulation of pleiotropic growth factors, receptors and
their downstream signaling pathway components repre-
sent a central protumorigenic principle in human hepato-
carcinogenesis [1]. Especially the Insulin-like Growth
Factor (IGF-1/IGF-1R), Hepatocyte Growth Factor (HGF/
MET), Wnt (Wnt/FZD), Transforming Growth Factor-
alpha/Epidermal Growth Factor (TGF-α/EGF/EGFR) and
Transforming Growth Factor-beta (TGF-β/TGF-βR) path-
ways contribute to proliferation, antiapoptosis and inva-
sive behavior of hepatocellular carcinoma cells [1-4]. It
has been shown that caveolae formation and/or expres-
sion of Caveolin-1 (Cav-1) affects the biological conse-
quences of such signaling pathways via particular
mechanisms including receptor internalization [5-7].
Although there is little evidence about involvement of
Cav-1 expression in hepatocarcinogenesis, the role of Cav-
1 is not clarified completely. Recently, it was found that
Cav-1 is essential for liver regeneration and plays a crucial
role in liver proliferation in response to partial hepatec-
tomy in mice [8]. Mechanisms of liver regeneration proc-
esses have been suggested to be similar with
hepatocarcinogenesis [9,10]. Generally, cell proliferation
occurs in both liver regeneration and malignant tumor
growth, but regeneration process is controlled stringently
whereas tumorigenesis is uncontrolled.
Cav-1 is a cell surface plasma membrane protein that is
necessary and sufficient for the formation of caveolae
invaginations on cell membrane [11]. Caveolae and Cav-
1 participate together in several cellular processes such as
vesicular transport, lipid metabolism, cholesterol home-
ostasis, and regulation of signal transduction including
cell cycle, growth and apoptosis [12]. Additionally, Cav-1
has been implicated in the pathogenesis of oncogenic cell
transformation and tumorogenesis. It was shown that dif-
ferences in Cav-1 expression depend on the type of tumor
cells. For instance, while Cav-1 downregulation is typical
for ovarian, lung, and mammary carcinomas, it is upregu-
lated in bladder, esophagus, thyroid and prostate carcino-
mas [13]. Furthermore, Cav-1 represents an acquired
feature that contributes to metastatic phenotype in differ-
ent types of carcinomas [14,15]. A growing body of evi-
dence suggests Cav-1 plays an essential role during
development of HCC. Yokomori et al. reported that Cav-
1 expression elevated in cirrhotic liver, while it was almost
undetectable in normal liver, and it may be associated
with significant reduction in nitric oxide catalytic activity
in cirrhosis [16]. On the other hand, it was shown that
Cav-1 expression was inactivated in HCC cell lines by
aberrant methylation and it may serve as important
biomarkers of malignancy [17]. These observations do
not provide clear evidence about the role of Cav-1 in
hepatocellular carcinogenesis. In a few studies, it was
shown that caveolae functions to compartmentalize cer-
tain proteins which bind directly to Cav-1 and regulate
signaling in HCC. For instance, deleted in liver cancer-1
(DLC1) and Tensin-2 proteins bind to Cav-1 and this
complex interacts with Rho GTPases in caveolae to effect
cytoskeletal reorganization in HCC cell lines [18]. How-
ever, the distribution and significance of Cav-1 expression
in normal and cirrhotic liver and the role in hepatocellu-
lar carcinogenesis still remain poorly understood.
In this study, we aimed to identify the expression status of
Cav-1 in normal, cirrhotic, and HCC tumor samples, in
order to investigate the changes in Cav-1 expression dur-
ing progression from normal liver to cirrhosis and HCC.
We complemented these descriptive analyses by studying
its in vitro cellular effects, following stable expression in
HCC cell lines and disruption of caveolae with chemical
inhibitors.
Methods
Cell Culture
Human hepatocellular carcinoma cell lines Huh7,
HepG2, Hep3B, SK-Hep1, SNU-398, SNU-449, SNU-475,
PLC/PRF-5 and Mahlavu [19] were cultured in DMEM
supplemented with 10% FBS, 100 u/ml penicillin, 0,1
mg/ml streptomycin and 2 mM L-glutamine in a CO2
incubator at 37°C. All cell culture reagents were pur-
chased from Biological Industries (Israel). HCC cell lines
were kindly provided by Dr. Mehmet Ozturk (Bilkent
University, Ankara, Turkey).
Immunoblotting and Gelatin-Zymography
Total cell lysates were prepared from HCC cell lines with
RIPA buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 1 mM
EDTA pH 8.0, %1 NP-40, 1X protease inhibitor cocktail, 1
mM NaF, 1 mM Na3VO4). Protein concentrations were
determined using BCA assay under manufacturer's
instructions (Pierce, IL, USA). 50 ug of total cell lysates
were boiled with Laemli buffer (Applichem, Darmstadt,
Germany) and loaded onto SDS-PAGE. Resolved proteins
were transferred onto PVDF membranes (Millipore, MA,
USA) and immunoblotted with appropriate antibodies.
Primary antibodies were purchased: Cav-1 (sc-894), cal-
nexin (sc-11397), E-cadherin (sc-8426), MMP-2 (sc-
13595), MMP-9 (sc-21733), MT1-MMP (sc-30074) from
Santa Cruz (California, USA); Vimentin (550513) from
BD Pharmingen (BD Biosciences, CA, USA); HRP-conju-
gated anti-rabbit and anti-mouse secondary antibodies
from Pierce. Proteins were detected using ECL detection
system (Pierce, IL, USA).
For the gelatin-zymography assays, cells were grown in
serum-free medium for 24 hrs and culture supernatant
was directly used for detection of secreted MMPs. Briefly,
40 ul of medium was loaded onto 7.5% polyacrylamide
gel containing 1 mg/ml gelatin. The gels were washed inBMC Cancer 2009, 9:65 http://www.biomedcentral.com/1471-2407/9/65
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2.5% Triton X-100 and then incubated in 50 mM Tris-Cl
(pH 7.0) solution containing 10 mM CaCl2 and 150 mM
NaCl at 37°C for 24 hrs. Following incubation, the gels
were stained with 0.25% commasive-blue for 1 hr and
destained with destaining-buffer (40% methanol, 20%
acetic-acid) until bands become clear. All chemicals were
purchased from Applichem (Darmstadt, Germany).
Preparation of stable cell-lines
Cav-1 cDNA was amplified from human HCC cell line
Mahlavu with Pfu DNA polymerase (MBI Fermentas,
Ontario, Canada), cloned into pcDNA3.1/Myc-His
expression vector (Invitrogen, CA, USA) using T4 DNA
ligation kit (Takara Bio, Shiga, Japan). Plasmid maxiprep-
aration kit was from Qiagen. Plasmids were controlled
with sequencing (Macrogen Inc., Seoul, Korea). Con-
structed pcDNA3.1/CAV1 vector was transfected into
HepG2 and Huh7 cells using TransFast reagent (Promega,
WI, USA). Transfected cells were treated with 1000 ug/ml
Geneticin (Gibco BRL, CA, USA) for HepG2 and 500 ug/
ml for Huh7. After 3-weeks of incubation, Geneticin-
resistant colonies were picked-up with cloning cylinders.
Stable colonies were controlled for caveolin-1 expression
by western-blotting.
In-vitro motility and invasion assays
The motility of parental and Cav-1 transfected HepG2 and
Huh7 cells in modified Boyden chambers were measured
using 8 um pore size of Biocoat Cell Environment control
inserts (BD Biosciences, CA, USA). Briefly, 70% confluent
cells were starved over-night with DMEM containing 1%
FBS. Lower chambers were filled with 750 ul of DMEM
containing 10% FBS. Starved cells were trypsinized,
washed in DMEM and added to upper chambers (2 × 106
cells/ml) and incubated at 37°C for 24 h. After incuba-
tion, media were removed; cells were fixed with methanol
and stained with Diff Quick (Siemens Healthcare Diag-
nostics, IL, USA). Cells on the upper surface of each mem-
brane were removed with cotton swabs, whereas cells that
had transversed to the bottom surface of the filters were
counted using brightfield microscope. Total cell numbers
were counted for each wells. The ratio of Cav-1 transfected
to parental migrating cells is designated on the y axis as
"migration (-fold increase)" +/- standard deviation.
Huh7 and HepG2 cell invasion assays were performed
using Matrigel Invasion Chambers (BD Biosciences, CA,
USA) and quantitated as described for cell migration
across uncoated membranes. Briefly, cells were seeded at
2 × 106 cells/ml in serum-free DMEM + 0,1%BSA and
placed into 24-wells culture plates containing DMEM +
5% FBS for 24 h at 37°C. The ratio of Cav-1 transfected
cells to parental invading cells is designated on the y axis
as "invasion (-fold increase)" +/- standard deviation. All
experiments were repeated at least three times.
For the disruption of caveolae structure, a cholesterol
depleting-agent methyl-β-cyclodextrin (MBCD) was used
as described previously [20]. Briefly, near-confluent cells
were washed with PBS and incubated 1 hour with serum-
free DMEM containing 10 mM MBCD (Sigma-Aldrich,
MO, USA). After treatment, cells were trypsinized,
counted and used for motility and invasion experiments.
Colony formation in soft-agar
The anchorage-independent growth of parental and Cav-
1 expressing Huh7 and HepG2 cells were determined by
assaying colony formation in soft-agar as described by
Koleske et al. with some modifications [21]. Briefly, single
cell suspension of parental and caveolin transfected cells
were prepared by trypsinization and homogenization.
Cells were suspended in DMEM containing 10% FBS as 5
× 105 cell/ml. Cells were plated onto each well of a 24-well
plate at a density of 2500 cells/well in DMEM containing
10% FBS and 0.4% low melting point agarose (Sigma,
MO, USA) on a base layer of 0.6% low melting point aga-
rose (Sigma, MO, USA). The medium was refreshed every
3 days. The number of colonies was counted and photo-
graphed after 2–3 weeks of incubation at 37°C. The assays
were performed in triplicate and repeated at least three
times.
Tissue samples and immunohistochemistry
Tissue samples were obtained from 95 patients with HCC
in cirrhotic background and other 29 patients with cirrho-
sis who underwent complete resection without any preop-
erative treatment in Dokuz Eylul University and Ege
University Hospitals in Izmir, Turkey. Liver biopsies taken
as a part of the evaluation of potential donors for living
donor liver transplantation at Ege University Hospital
were used as control normal liver tissue (n = 20). The
study was approved by the Ethics Committees of both
Dokuz Eylul and Ege University Medical Schools. Written
informed consents from patients were obtained before
liver transplantation or liver biopsy sampling. All tissue
samples were fixed in formalin and embedded in paraffin,
standard 5 μm tissue sections were obtained and stained
with hematoxylen-eosin and examined by light micros-
copy. The histopathological diagnosis of all patients was
carried out by the WHO histopathological classification of
liver and intrahepatic bile ducts [22]. Each slide was inde-
pendently evaluated by two pathologists unaware of clin-
icopathological characteristics of the tumor.
For immunostaining, paraffin embedded tissues were
deparaffinized in xylene and were rehydrated. Immunos-
taining was performed using an automated immunohis-
tochemical stainer according to the manufacturer's
guidelines (IVIEW™ DAB, BenchMarkXP, Ventana, USA).
The antigen retrieval step was included in the automated
programme. Endogenous peroxidase activity was blockedBMC Cancer 2009, 9:65 http://www.biomedcentral.com/1471-2407/9/65
Page 4 of 12
(page number not for citation purposes)
by 3% H2O2 for 4 minutes at 37°C. Endogenous avidin
biotin activity was blocked by the avidin-biotin block
solution (DAKO, Denmark). Sections were incubated
with anti-caveolin-1 (sc-894) antibody at 1:100 dilution.
The reaction product was developed using 3,3-diami-
nobenzidine tetrahydrochloride (DAB) and sections were
counterstained with hematoxylin. Sections were then
evaluated by two pathologists (FY, DN) who were blinded
to the clinical information on patients. Positive staining
was defined as membranous and/or cytoplasmic expres-
sion. The extent of caveolin expression was semiquantita-
tively graded as 0 (less than 10% of the cells), 1+
(positivity between 10%–50% of cells), and 2+ (more
than 50% of cells). The intensity of caveolin expression
was semiquantitatively graded as 0, 1 or 2. Additionally,
profile of caveolin expression was investigated by compar-
ing staining intensities in the tumor cells with respect to
its surrounding tissue and graded as above.
Statistical analysis
Statistical analysis of obtained data was performed using
the SPSS-Software. Correlation analysis between Cav-1
expression and clinicopathological data including infor-
mation on TNM classification, histopathological grading,
number of tumor nodules, tumor size, presence of venous
invasion and tumor etiology was performed using cross-
tables applying χ2 test. A P-value of ≤ 0.05 was considered
as indicative of statistical significance for the tests used.
Results
Caveolin-1 expression is correlated with differentiation 
and motility status of HCC cell lines
We studied Cav-1 expression in HCC cell lines by western
blotting. Caveolin-1 was expressed in 4 cell lines (SNU-
449, SNU-475, SK-Hep1, and Mahlavu), but not in 5 oth-
ers (SNU-398, HepG2, Hep3B, PLC/PRF-5 and Huh7), as
shown in Figure 1. When we analyzed differentiation sta-
tus of these HCC cell lines according to HNF1α, 3α, 3β,
4α and 6 expressions, HepG2, Hep3B, PLC/PRF-5 and
Huh7 formed a group of well differentiated cell lines,
whereas others formed another subgroup of poorly differ-
entiated cell lines (E. Erdal et al.; unpublished data). Thus,
Cav-1 expression was closely related to the differentiation
status of these cell lines. It was not expressed in well-dif-
ferentiated cell lines, whereas 4 out of 5 poorly differenti-
ated cell lines displayed high levels of Cav-1 expression
(Table 1). Moreover, motility capacity of these HCC cell
lines [23] was positively correlated with Cav-1 expressions
as shown in Table 1.
Increased expression of Caveolin-1 in cirrhotic and HCC 
tissue samples compared to normal liver
In order to investigate Cav-1 expression in different stages
of hepatocellular carcinogenesis, we analyzed its expres-
sion profile by immunoperoxidase staining of normal
liver (n = 20), cirrhosis (n = 29), and HCC (n = 95) tissue
samples. The age of HCC patients ranged from 39 to 65
years (mean 53 ± 6 years). Of the 95 patients, 80 were
men and 15 were women. Clinicopathological character-
istics of HCC patients were summarized in Table 2.
In normal liver tissues, there were very weak staining in
hepatocytes for Cav-1, except one tissue that displayed
moderately positive staining. In all normal tissues,
endothelium of blood vessels were strongly positive, as
expected (Figure 2A). In cirrhotic livers, we observed pos-
itive staining in 13 of 29 (45%) samples (Figure 2B).
Finally, in 62 of 95 (65.3%) HCC samples, tumor cells
Expression of Cav-1 protein in HCC cell lines Figure 1
Expression of Cav-1 protein in HCC cell lines. SNU-475, Mahlavu, SK-Hep1 and SNU-449 express caveolin-1 while 
Huh7, HepG2, Hep3B, SNU-398 and PLC/PRF-5 do not express it (Calnexin was used as internal control for western blotting).BMC Cancer 2009, 9:65 http://www.biomedcentral.com/1471-2407/9/65
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stained positively for Cav-1 (Figures 2C and 2D). Out of
95 HCC samples, only 6 samples have weak caveolin
staining in the tumor cells compared with its surrounding
tissue. Also, caveolin-1 expression in the tumor cells was
significantly stronger than the cells in surrounding tissue
when analysed all HCC samples (p < 0.001) (Figure 2E).
Statistical analysis of normal liver, cirrhosis and HCC data
showed that the increase in cirrhosis and HCC was signif-
icant (p = 0.002 when HCC was compared to cirrhosis;
and p < 0.001 when HCC or cirrhosis were compared to
normal tissues) (Figure 2F).
Since we observed a close correlation between Cav-1
expression and differentiation status of HCC cell lines, we
also compared Cav-1 expression with respect to differen-
tiation status of HCC tissues. 8 of 18 (44%) well differen-
tiated HCC tissues, 39 of 60 (65%) moderately
differentiated HCCs, and 15 of 17 (88%) poorly differen-
tiated HCCs were positive for Cav-1 (Table 2), indicating
that Cav-1 expression is also closely related to differentia-
tion status of primary HCC tumors (p = 0.001). We also
noticed that, whereas majority of Cav-1 staining was
membranous in well- and moderately differentiated HCC
samples, the staining in poorly differentiated HCCs was
strongly cytoplasmic (Figure 2C and 2D).
Besides differentiation status, Cav-1 expression was also
analyzed according to other clinicopathological factors
such as age, sex, portal vein invasion and etiology. A
strong correlation was found between Cav-1 expression
and the presence of venous invasion of HCC samples (p =
0.02), but there was no statistically significant correlation
with tumor size, tumor etiology, number of tumor nod-
ules, age and gender (Table 2). For cirrhotic tissues, Cav-1
expression showed no correlation with etiology or gender
(data not shown).
Table 1: Differentiation status and caveolin-1 expressions of HCC cell lines.
Cell Lines Differentiation Status Motility Status Caveolin Expression (protein level)
Huh7 well - -
Hep3B well - -
HepG2 well - -
PLC/PRF-5 well ND* -
SNU-398 poorly - -
SNU-475 poorly + +
SNU-449 poorly + +
SK-Hep1 poorly + +
Mahlavu poorly + +
*Not Determined
Table 2: Clinicopathological characteristics of primary hepatocellular carcinoma patients.
Caveolin-1
Parameters Variable No. of patients (+) % p*
Gender Male 80 53 66.3 0.833
Female 15 9 60
Tumor size < 5 cm 78 51 65.4 0.833
> 5 cm 17 11 64.7
Etiology Hepatitis viruses 79 52 65.8 0.601
Non-viral 11 7 63.6
Unknown 5 3 60
Number of tumor nodules < 3 43 29 67.4 0.580
> 3 52 33 63.5
Venous invasion Present 38 29 76.3 0.02**
Absent 57 33 57.9
Tumor grade (a) Well differentiated 18 8 44.4 < 0.001**
Moderately differentiated 60 39 65.0
Poorly differentiated 17 15 88.2
* X2, ** Statistically significant
(a) All of the HCC tissues used in this study are in a cirrhotic background.BMC Cancer 2009, 9:65 http://www.biomedcentral.com/1471-2407/9/65
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Immunohistochemical staining of Cav-1 in normal, cirrhotic and HCC tissue sections Figure 2
Immunohistochemical staining of Cav-1 in normal, cirrhotic and HCC tissue sections. (A) Absence of Cav-1 
expression in hepatocytes of normal donor liver tissue and strong Cav-1 expression in the endothelium of the blood vessels. 
(B) Cav-1 positivity in the cirrhotic nodule and endothelium of the vessels with same intensity. (C) Membranous Cav-1 posi-
tivity in one of the well differentiated HCC cases. (D) Strong cytoplasmic Cav-1 expression in a poorly differentiated HCC. 
(E) Staining of Cav-1 in an HCC sample with its tumoral and surrounding peritumoral region. (F) The percentage of Cav-1 
staining in normal liver, cirrhosis and HCC tissues (* p < 0.001 when HCC and cirrhotic tissues were compared to normal 
liver; ** p = 0.002 when HCC was compared to cirrhotic tissues). Normal liver tissues, cirrhotic tissues (without HCC) and 
HCC tissues are taken from different patients.BMC Cancer 2009, 9:65 http://www.biomedcentral.com/1471-2407/9/65
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Expression of Caveolin-1 affects cell motility and invasion
In order to investigate the role of Cav-1 expression on cell
motility and invasion ability of HCC cells, we stably trans-
fected pcDNA3.1/CAV1 construct into Huh7 and HepG2
cells in which endogenous Cav-1 expression was weak or
negative, respectively. Cav-1-expressing clones and paren-
tal cells were analyzed in parallel by using motility/inva-
sion chambers, as described in methods. Overexpression
of Cav-1 caused approximately two fold increase both in
cell motility and invasion with respect to parental and
control vector transfected Huh7 and HepG2 cells (Figure
3). Moreover, motility and invasion of SNU-475 and
SNU-449 cells which express Cav-1 endogenously, were
analysed after caveolae structures were disrupted by addi-
Effect of caveolin-1 expression on the cellular migration and invasion of HCC cell lines Figure 3
Effect of caveolin-1 expression on the cellular migration and invasion of HCC cell lines. (A) Ectopic expression of 
Cav-1 in Huh7 and HepG2 cells were shown by western blotting in comparison with parental cells. Stably transfected caveolin-
1 producing HepG2 (B, D) and Huh7 (C, E) cells with their parental cells and vector-transfected stables clones (mock) were 
assayed for their ability of migration and invasion. Data includes mean ± SD values from three independent experiments and 
each experiment was performed as triplicate.BMC Cancer 2009, 9:65 http://www.biomedcentral.com/1471-2407/9/65
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tion of cholesterol depleting-agent methyl-β-cyclodextrin
(MBCD) into the culture medium. Caveolae disruption
caused approximately 2-fold and 10-fold decrease in the
motility of SNU-449 and SNU-475, respectively (Figure
4A). Additionally, caveolae distruption caused almost
complete inhibition of invasion in both SNU-449 and
SNU-475 cells (Figure 4B). Thus, we concluded that Cav-
1 expression in HCC cells might contribute cellular motil-
ity and invasion of these cells.
Caveolin-1 induces both an Epithelial Mesenchymal 
Transition (EMT)-like phenotype and the expression of 
Matrix Metalloproteinases in HCC cells
To determine the molecular mechanisms behind the
increase in the motility and invasion under the effect of
Cav-1 overexpression in HepG2 and Huh7 cells, we ana-
lysed the expression of main EMT markers in these cells.
As shown in Figure 5A, E-cadherin protein level was
down-regulated while Vimentin level was up-regulated in
Cav-1 overexpressing Huh7 and HepG2 cells compared
with parental ones. These results were consistent with the
phenomena in the epithelial to mezenchymal transition
(EMT). In addition, we analysed the cellular and secreted
forms of Matrix Metalloproteinases (MMPs) in these cells
by western-blotting and gelatin-zymography assays,
respectively. Among the secreted MMPs, only MMP-2 was
found as increased in Cav-1 expressing HepG2 cells (Fig-
ure 5B). Further in cell-lysates, MMP-9 and MT1-MMP
were found as up-regulated in HepG2 cells overexpressing
Cav-1 (Figure 5C). Taken together with EMT-phenotype,
these results may explain the increased cellular motility
and matrix invasion of HCC cells.
Caveolin-1 does not affect anchorage-independent growth 
of HCC cells in vitro
To evaluate the role of Cav-1 in the anchorage-independ-
ent growth in HCC cells, Cav-1-expressing clones and
parental cells were used. Huh7 and HepG2 clones
strongly expressing ectopic Cav-1 were analyzed for their
abilities to form colonies in soft agar in comparison with
their parental counterparts. Both Cav-1 expressing clones
and parental cells formed high number of colonies in soft
agar and there were no significant difference regarding on
the colony size and the number (Figure 6).
Discussion
Cav-1 expression was reported to be mostly stage-depend-
ent during tumorigenesis. It is known to be absent or
reduced following gene promoter-CpG-island hyper-
methylation in early-stage tumors, but re-expressed (by
gene promoter-mCpG-DNA demethylation) in late-stages
of different carcinomas such as metastasized lung, pros-
tate, gastric carcinomas, as well as sarcomas [24]. This
biphasic stage-dependent expression pattern of Cav-1
may not be valid for hepatocellular carcinogenesis. Yoko-
mori et al. reported elevated expression of Cav-1 at protein
and mRNA levels in a small set of cirrhotic livers (n = 5)
[16]. Anders et al. also showed elevated Cav-1 expression
in macroregenerative and dysplastic nodules which are
precursor lesions of HCC [25]. Our data clearly indicate
that Cav-1 is overexpressed in both premalignant cirrhotic
tissues and malignant HCC tumors when compared to
normal liver samples. Also, caveolin-1 is highly expressed
in tumor cells more than their peritumoral cirrhotic
regions in HCC tissues. This observation may be
explained by different microenvironments due to the
The effect of caveolae disruption on motility and invasion of endogenously Cav-1 expressing SNU-449 and SNU-475 cells Figure 4
The effect of caveolae disruption on motility and invasion of endogenously Cav-1 expressing SNU-449 and 
SNU-475 cells. To determine the effect of caveolae disruption on motility and invasion of SNU-449 and SNU-475 cells, we 
used a cholesterol-depleting agent methyl-β-cyclodextrin (MBCD), as described in methods section. The effect of caveolae dis-
ruption on motility (A) and invasion (B) of both SNU-449 and SNU-475 cells was shown. Data includes mean ± SD values 
from two independent experiments and each experiment was performed as triplicate.BMC Cancer 2009, 9:65 http://www.biomedcentral.com/1471-2407/9/65
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presence of tumor. Based on these data, it is strongly
proven that overexpression of Cav-1 might contribute to
progression of hepatocellular carcinogenesis. Thus, it can
be proposed as a tumorigenesis marker for HCC.
Functional role of Cav-1 appears to differ depending on
the tumor cell type and/or tumor stage. In human prostate
cancers, Cav-1 expression correlates positively with extra-
prostatic extension and lymph node involvement [26]. In
the same study, the involvement of Cav-1 also has been
clearly proven in mediating angiogenesis during prostate
cancer progression. On the other hand, Williams et al.
reported that Cav-1 is a potent suppressor of mammary
tumor growth and metastasis in an animal model [27].
The functional role of Cav-1 in HCC remains elusive. In
our studies, when Cav-1 was overexpressed ectopically in
HCC cell lines, cells displayed increased motility and
invasion. And when caveolae was disrupted by chemicals,
abilities on the motility and invasion were decreased as
well. Moreover, we observed a statistically significant pos-
itive correlation between venous invasion and Cav-1
expression in HCC tumor samples and showed that motil-
ity status of HCC cell lines are positively correlated with
Cav-1 expressions in these cell lines. Taken together, these
observations indicate that Cav-1 may functions as a pro-
moter of motility and invasion in HCC. Additionally, we
demonstrated that Cav-1 overexpression reduced prolifer-
ation of HepG2 cells whereas it did not affect proliferation
of Huh7 cells (data not shown). Since Cav-1 overexpres-
sion affects cell proliferation in a cell type dependent
manner, it may have a dual function in hepatocellular car-
cinogenesis.
The role of Cav-1 on cellular motility and invasion is not
well understood in tumorigenesis. Recently, it was shown
that membrane-type-1 matrix metalloproteinase (MT1-
MMP) co-localizes with Cav-1 at the perinuclear region
and it may be translocated to the nucleus via caveolae-
mediated endocytosis in HCC [28]. A correlation between
nuclear MT1-MMP and tumor aggressiveness including
poor prognosis and large tumor expansion has been
reported. Furthermore, Jia et al. demonstrated that Cav-1
expression leads to an increased production of MMP-11
and increased invasive capability in murine HCC cell lines
[29]. Giannelli et al., showed that MMP2 and MT1-MMP1
expressions stimulate invasion of HCC cell lines [30].
Consistent with these studies, we showed Cav-1 overex-
pression caused an increase in the MMP-2 secretion to cul-
ture supernatant and in expression of MMP-9 and MT1-
MMP in HCC cell-lines.
It is very well known that expressional changes from E-
cadherin, an epithelial marker to Vimentin, a mesenchy-
mal marker shows EMT phenotype for epithelial cells.
EMT contributes invasive and metastatic phenotype in
progression of epithelial tumors such as HCC [31]. It pre-
viously has been shown that regulation of Cav-1 plays a
central role in the complex cellular changes leading to
metastasis via epithelial-to-mesenchymal transition in
human tumor cells overexpressing EGFR [15]. In our
Molecular changes in Cav-1 overexpressing Huh7 and HepG2 cells Figure 5
Molecular changes in Cav-1 overexpressing Huh7 and HepG2 cells. (A) Expression levels of E-cadherin and Vimentin 
in Cav-1 overexpressing and parental Huh7 and HepG2 cells. (B) Gelatin-zymography result of MMP-2 secreted to the culture 
supernatant of parental and Cav-1 overexpressing HepG2 cells. (C) Expression levels of MMP-9 and MT1-MMP in parental and 
Cav-1 overexpressing HepG2 cells. All western-blotting and gelatin-zymography results were confirmed with at least two inde-
pendent experiments.BMC Cancer 2009, 9:65 http://www.biomedcentral.com/1471-2407/9/65
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Effect of Cav-1 overexpression on the anchorage-independent growth ability of HCC cells Figure 6
Effect of Cav-1 overexpression on the anchorage-independent growth ability of HCC cells. The number of colo-
nies formed in soft agar for stably Cav-1 overexpressing, mock-transfected and parental Huh7 cells (A) and HepG2 cells (B) 
were shown in the graphic. Each experiment was performed in triplicate and fields are representative of three independent 
experiments. Colonies are photographed at 20× magnification as shown at the bottom of the graphic for each.BMC Cancer 2009, 9:65 http://www.biomedcentral.com/1471-2407/9/65
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study, Cav-1 overexpression caused a decrease in the E-
cadherin, contrarily, an increase in Vimentin expression
levels. These changes are consistent with an epithelial to
mesenchymal transition and may explain the motility and
invasion increase observed in Cav-1 overexpressing HCC
cells.
Besides contribution of Cav-1 in HCC cell motility and
invasiveness, there was a strong correlation between dif-
ferentiation status and Cav-1 expression in both HCC cell
lines and tumor samples used in this study. We showed
that poorly differentiated HCC cell-lines abundantly
express Cav-1 with respect to well differentiated ones.
Recently, Fuchs et al. classified several HCC cell-lines
including which we used in this study as epithelial or mes-
enchymal according to their expressions of EMT markers
[32]. It is proposed that caveolin-1 expression might be
correlated with the status of differentiation of hepatocar-
cinogenesis via appearance of epithelial mesenchymal
transition following high invasiveness. It is known that
poorly differentiated HCC tumors are much more aggres-
sive and metastatic when compared to well or moderately
differentiated tumors [33,34]. Recently, it has also been
reported that distant metastasis within 2 years after a cur-
ative hepatectomy occurred more frequently in poorly dif-
ferentiated HCC group than in well or moderately
differentiated HCC groups [34]. Therefore, it may be con-
cluded that Cav-1 upregulation contributes to more inva-
sive capability in poorly differentiated HCCs.
Another interesting result obtained in our study that Cav-
1 localization in poorly-differentiated HCC tissues was
strongly cytoplasmic while it was membranous in well-
differentiated ones. Orlichenko et al. showed that caveo-
lae internalization and cytoplasmic localization occurs
only Cav-1 is phosphorylated by growth factor receptors
such as EGFR [35]. So, cytoplasmic Cav-1 staining in
poorly-differentiated HCC tissues shows that Cav-1 is
active and takes roles in these cells. Because Cav-1 is
known as a regulator for many growth factor signaling
pathways and many growth factor signaling is dysregu-
lated in HCC, Cav-1 may be a candidate regulating these
signaling events.
Conclusion
In conclusion, stepwise increase in Cav-1 expression in
neoplastic stage with respect to pre-neoplastic stage dur-
ing hepatocellular carcinogenesis and its ability to stimu-
late HCC cell motility and invasiveness indicate that this
protein plays a crucial role in tumor progression. This
opens new ways to use Cav-1 as a marker of tumor pro-
gression, as well as for the design of therapeutic
approaches aiming to block its cellular functions. Target-
ing Cav-1 in HCC may represent a potential option for
future HCC treatment.
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